GEN0101 / AnGes MG, TSD Japan - LARVOL DELTA

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma. (PubMed, Cancer Immunol Immunother) - "The activity of NK cells and interferon-γ levels were increased in the circulation, indicating augmentation of antitumor immunity by GEN0101. This trial showed not only the safety and tolerability but also the significant antitumor effect of GEN0101, suggesting that GEN0101 might be a promising new drug for patients with advanced melanoma."

Clinical • Journal • P1 data • Immune Modulation • Inflammation • Melanoma • Oncology • Solid Tumor • IFNG

Intratumoral and subcutaneous injection of HVJ-E (GEN0101) for metastatic castration-resistant prostate cancer: Open-label, phase I, dose escalation study. (ASCO 2019) - "Intratumoral and subcutaneous injections of GEN0101 were well tolerated and feasible. Antitumor effect in lymph node metastasis were observed in CRPC patients. It is necessary to test whether the treatment with GEN0101 improves the survival of CRPC patients."

Clinical

Intratumoral and subcutaneous injection of HVJ-E (GEN0101) in metastatic castration-resistant prostate cancer. (PubMed, Cancer Sci) - "In conclusions, intratumoral and subcutaneous injections of GEN0101 were well tolerated and feasible to use. The study is registered at UMIN Clinical Trials Registry, number UMIN000017092."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Open-label, phase I, dose escalation study to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E (GEN0101) in castration-resistant prostate cancer patients (EAU 2019) - No abstract available.

Clinical

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII (clinicaltrials.gov) - P2; N=46; Recruiting; Sponsor: Osaka University

Clinical • Combination therapy • New P2 trial